Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

References

• Gandhi SK, Arguelles L, Boyer G. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy 2001;21:684-90
   Google Scholar
• Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control 1996;3:519-23
   Google Scholar
• Siena S, Piccart M, Holmes F, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II–IV breast cancer. Oncol Rep 2003;10:715-24
   Google Scholar
• Lyman G, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-64
   Google Scholar
• Westermann AM, Taal BG, Swart M, et al. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. Pharmacol Res 2000;42:151-6
   Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069-76
   Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
   Google Scholar
• Smith T, Khatcheressian J, Lyman G, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   Google Scholar
• Klastersky J. Febrile neutropenia. Curr Opin Oncol 1993;5:625-32
   Google Scholar
• Johnston E, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol 1998;25:552-61
   Google Scholar
• Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-11
   Google Scholar
• Uyl-de Groot CA, Vellenga E, De Vries EG, et al. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomized placebo-controlled trial. Pharmacoeconomics 1997;12:351-60
   Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   Google Scholar
• Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl. 1):1-15
   Google Scholar
• Green M, Koelbl H, Baselga J, et al. A randomized, double-blind, multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   Google Scholar
• García-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8
   Google Scholar
• Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803-8
   Google Scholar
• Freifeld AG, Walsh TJ, Pizzo PA. Infection in the cancer patient. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice in Oncology. Philadelphia, USA: Lippincott-Raven, 1997: pp. 2659-99
   Google Scholar
• Grever HR, Chabner B. Cancer drug discovery and development. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice in Oncology. Philadelphia, USA: Lippincott-Raven, 1997: pp. 385-94
   Google Scholar
• Gisbert R, Brosa M. [CD-ROM database] Base de datos de Costes Sanitarios. SOIKOS Versión 2.2. Barcelona: Centre d’Estudis en Economía de la Salut i de la Política Social, 2005
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. [CD-ROM database]. BOT Plus: base de datos del conocimiento sanitario, 7th update (01/09/2005). Madrid: CGCOF, 2006
   Google Scholar
• Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30:S51-9
   Google Scholar
• Timmer-Bonte JNH, Adang EMM, Smit JHM, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 2006;24:2991-7
   Google Scholar
• Cosler LE, Eldar-Lissai A, Culakova E, et al. Therapeutic use of granulocyte colony-stimulating factor for established febrile neutropenia. Effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343-51
   Google Scholar
• Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129-46
   Google Scholar
• Bennet CL, Calhoun EA. Evaluating the total cost of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007;12:478-83
   Google Scholar
• Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implication for quality and cost of care. J Clin Oncol 2000;18:3699-706
   Google Scholar
• Leese B. The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 1993;29(Suppl. 7):S15-S18
   Google Scholar
• Leonard RC, Miles D, Thomas R, et al. UK Breast Cancer Neutropenia Audit Group. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-68
   Google Scholar